The Catalent Applied Drug Delivery Institute said today that it inked a deal to work with the dept. of pharmacy practice at Rutgers University in an effort to identify and address the challenges linked to pediatric drug formulation and delivery.
The collaboration plans to focus on the development and administration of medicines to children by identifying conditions that have a high need for kid-friendly formulations.
“Clinical experience has shown us that current pediatric drug formulations are often difficult to administer to children and increase the likelihood for a medication error when compared with adult formulations. There is a clear need for research in this area, to further elucidate the gaps in drug delivery for young children, and in order to improve therapeutic outcomes and the patient experience,” Rachel Meyers, from the Ernest Mario School of Pharmacy at Rutgers University, said in prepared remarks.
“Through this exciting partnership, we will examine and highlight the unmet scientific, clinical, and patient needs, and look to develop a suitable pediatric-specific drug formulation toolkit to address them,” Cornell Stamoran, founder of the Catalent Applied Drug Delivery Institute and Catalent’s VP of strategy, added. “Most initiatives focus on individual new drugs or disease areas – we’re collaborating to identify a broad platform, founded on rigorous stakeholder insights, to establish a foundation for future pediatric drug development.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.